NEW YORK – Infectious disease diagnostics firm MeMed said on Tuesday that it has received the CE mark for its COVID-19 management tool MeMed COVID-19 Severity.
The test measures multiple host-response proteins in serum to determine whether a COVID-19 patient is likely to experience severe outcomes, allowing doctors to distinguish between patients who may need higher levels of care and those who can safely self-isolate at home.
The test runs on Haifa, Israel-based MeMed's point-of-need platform, the MeMed Key, and returns results in 15 minutes.
“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians," Sergey Motov, professor of emergency medicine, Maimonides Medical Center, said in a statement. "Tools like MeMed COVID-19 Severity are a win-win solution: Doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low."
"I’m excited to begin deploying a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation," said Eran Eden, MeMed's cofounder and CEO. "MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics."
The company said it plans to offer the test in Europe both directly and through commercial partners.